top of page
  • Active, not recruiting

NCT05032820: Phase 2: MM CAR-T to Upgrade Response BMT CTN 1902

Updated: Feb 10

  • BMT CTN 1902

  • NCT05032820: Phase 2: MM CAR-T to Upgrade Response BMT CTN 1902

BMT CTN 1902

MM CAR-T to Upgrade Response BMT CTN 1902

This study is designed as a Phase II, multicenter, single arm trial to assess anti-B Cell Maturation Antigen (BCMA) chimeric antigen receptor (CAR) T-cells (bb2121) to improve post autologous hematopoietic cell transplant (HCT) responses among patients with multiple myeloma (MM).


Marcelo Pasquini, MD


National Heart, Lung, and Blood Institute (NHLBI)

Blood and Marrow Transplant Clinical Trials Network

National Cancer Institute (NCI)

National Marrow Donor Program

Celgene a wholly owned subsidiary of BMS

Information provided by (Responsible Party)

Marcelo Pasquini, MD, Medical College of Wisconsin

Multiple Locations Identifier: NCT02786511

Official Title: Phase II Multicenter Trial of Anti-BCMA CAR T-Cell Therapy for MM Patients With Sub-Optimal Response After Auto HCT and Maintenance Len. BMT CTN 1902

First Posted : September 2, 2021

Click here for details on


Drug: Lenalidomide and bb2121



United States, California

United States, Florida

United States, Illinois

United States, Massachusetts

United States, New York

United States, North Carolina

United States, Pennsylvania

United States, Virginia

United States, Wisconsin


Commenting has been turned off.
Posts Archive
bottom of page